Published in Diabetol Metab Syndr on May 25, 2017
Diabetes mellitus. Report of a WHO Study Group. World Health Organ Tech Rep Ser (1985) 6.63
Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int (2011) 6.01
Understanding and using sensitivity, specificity and predictive values. Indian J Ophthalmol (2007) 3.05
The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes (1983) 2.56
Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol (2014) 2.34
Impact of HbA1c, followed from onset of type 1 diabetes, on the development of severe retinopathy and nephropathy: the VISS Study (Vascular Diabetic Complications in Southeast Sweden). Diabetes Care (2014) 2.13
Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care (2010) 2.06
Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol (2010) 1.92
Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int (2011) 1.91
Early urinary markers of diabetic kidney disease: a nested case-control study from the Diabetes Control and Complications Trial (DCCT). Am J Kidney Dis (2010) 1.79
Soluble CD163. Scand J Clin Lab Invest (2011) 1.72
IL-33/ST2 axis in inflammation and immunopathology. Immunol Res (2012) 1.62
Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia (2009) 1.59
Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study. Diabetes (2013) 1.37
Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation (2013) 1.32
Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond) (2015) 1.14
Serum soluble CD163 predicts risk of type 2 diabetes in the general population. Clin Chem (2010) 1.12
Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure. J Card Fail (2015) 1.11
Signs of nephropathy may occur early in young adults with diabetes despite modern diabetes management: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care (2003) 1.08
Relationship between retinal and glomerular lesions in IDDM patients. Diabetes (1994) 1.07
Renal lesions predict progression of diabetic nephropathy in type 1 diabetes. J Am Soc Nephrol (2013) 1.01
Soluble CD163: a biomarker linking macrophages and insulin resistance. Diabetologia (2012) 0.99
Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes. Diabetes Care (2015) 0.97
The macrophage-specific serum marker, soluble CD163, is increased in obesity and reduced after dietary-induced weight loss. Obesity (Silver Spring) (2013) 0.96
Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. a case-control study. PLoS One (2012) 0.95
Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new inflammatory pathway of relevance to diabetes? PLoS One (2012) 0.94
TWEAK: A New Player in Obesity and Diabetes. Front Immunol (2013) 0.88
Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study. Clin Chem (2014) 0.88
Diabetic retinopathy--biomolecules and multiple pathophysiology. Diabetes Metab Syndr (2014) 0.87
Toll/interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction. Cardiovasc Diabetol (2011) 0.87
Albuminuria and renal function as predictors of cardiovascular events and mortality in a general population of patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register. Diab Vasc Dis Res (2013) 0.85
Renal impairment and all-cause mortality in cardiovascular disease: effect modification by type 2 diabetes mellitus. Eur J Clin Invest (2013) 0.84
CD163 interacts with TWEAK to regulate tissue regeneration after ischaemic injury. Nat Commun (2015) 0.83
Rapid GFR decline is associated with renal hyperfiltration and impaired GFR in adults with Type 1 diabetes. Nephrol Dial Transplant (2015) 0.82
The incidence of nephropathy in type 1 diabetic patients with proliferative retinopathy: a 10-year follow-up study. Diabetes Res Clin Pract (1998) 0.81
Soluble CD163 is associated with body mass index and blood pressure in hypertensive obese Saudi patients. Eur J Clin Invest (2012) 0.81
Predictors of cardiovascular autonomic neuropathy in patients with type 1 diabetes. Front Endocrinol (Lausanne) (2014) 0.79
Activated mast cells synthesize and release soluble ST2-a decoy receptor for IL-33. Eur J Immunol (2015) 0.79
The tumor necrosis factor superfamily members TWEAK, TNFSF15 and fibroblast growth factor-inducible protein 14 are upregulated in proliferative diabetic retinopathy. Ophthalmic Res (2015) 0.78
sST2 levels are associated with all-cause mortality in anticoagulated patients with atrial fibrillation. Eur J Clin Invest (2015) 0.76
Biomarkers of Renal Disease and Progression in Patients with Diabetes. J Clin Med (2015) 0.75
Role of cannabinoid receptor 1 in human adipose tissue for lipolysis regulation and insulin resistance. Endocrine (2016) 0.75
Markers of fibrinolysis may predict development of lower extremity arterial disease in patients with diabetes: A longitudinal prospective cohort study with 10 years of follow-up. Diab Vasc Dis Res (2016) 0.75
3-Hydroxyisobutyrate, A Strong Marker of Insulin Resistance in Type 2 Diabetes and Obesity That Modulates White and Brown Adipocyte Metabolism. Diabetes (2020) 0.75